Ebola Resources

In October 2014, the Ebola outbreak in West Africa was at an all-time high. In response to the widespread coverage of the Ebola virus, CHEST hosted late-breaking Ebola-focused sessions during CHEST 2014 in Austin, Texas. These sessions featured health professionals who have been on the front lines of the Ebola outbreak in West Africa, clinicians who have experienced Ebola in the United States, and other experts in virology, epidemiology, and disaster preparedness.

Below are materials from our CHEST 2014 Ebola coverage. Check back as we add more.

Videos | Resources | Social Media | News Highlights


CHEST 2014 Ebola-focused Sessions

The playlist below features each Ebola-focused session held during CHEST 2014. To view all session options, click "Playlist" in the upper left corner of the video image. Download Dr. Weinstein's presentation slides.

Ebola Interviews from CHEST 2014

The playlist below features individual interviews with experts on various Ebola-focused topics. To view all video topics, click "Playlist" in the upper left corner of the video image.

PPE Demonstration

Dr. Edgar Jimenez talked through the donning and doffing procedure for Ebola preparedness at CHEST 2014. Click the image below to view the entire demonstration.

Additional Resources

Experts from our Ebola-focused sessions recommended the following resources in planning for the care of patients with Ebola.

Successful Delivery of RRT in Ebola Virus Disease

Emory Healthcare Ebola Preparedness Protocol 

Nebraska Medicine Ebola Resources and Protocols

CDC Ebola Information for Health-care Workers and Settings

Care of the Critically Ill and Injured During Pandemics and Disasters: CHEST Consensus Statement

Ebola Clinical Care Guidelines: A guide for clinicians in Canada
Source: Canadian Critical Care Society, Canadian Association of Emergency Physicians, and Association of Medical Microbiology and Infectious Diseases Canada

CHEST Podcast: Planning for Care During Pandemics and Disasters

The PDFs below have been provided by Baylor Scott and White Health (BSWH).**

Algorithm for OB Patient Screening
Algorithm for Patient Screening
Algorithm for Transporting Patient - North Texas
Ebola Virus Screening and Risk Assessment Form
Ebola Virus Screening and Risk Assessment Form - Spanish
Ebola Virus Screening and Risk Assessment Form - Vietnamese
Ethics Statement
FAQ for Call Centers, Contact Centers, and Operators
FAQ for Caregivers with Direct Ebola Patient Contact
Laboratory Testing Guidelines
Room Cleaning and Waste Control
Room Entry Log
Screening PPE Breach and Screening Staff Exposure
Screening PPE
Treatment PPE Breach and Treatment Staff Exposure
Treatment PPE for Health-care Worker and Coach

** These protocols are for the exclusive use of Baylor Scott and White Health (BSWH). They are not intended to render medical advice, make recommendations, or mandate the adoption and use of these materials outside BSWH. These materials are specific to BSWH’s processes and available equipment, including the ILC Dover PAPR. The materials are not intended to be a substitute for the updates and guidelines published by the Centers for Disease Control and Prevention, the applicable local health department, and any other authority on this matter.

Back to Top

#EbolaCHEST Storify

Back to Top

CHEST Ebola News Highlights

American College of Chest Physicians to Provide Late-Breaking Resources and Education on Ebola at CHEST 2014

Ebola, the Asthma Epidemic, and the Microbiome at CHEST 2014 (requires free account login)

From Headlines to Bedside: Ebola at CHEST 2014

Common Sense Ebola Measures Save Lives in Africa, Teach US

How U.S. health providers can contain Ebola (video below)

Back to Top

="http://clinicaltrials.gov/ct2/show/NCT01922037?term=ML28528&rank=1">Learn how to participate  

Lavolta I

Lavolta II 

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
(LAVOLTA I and LAVOLTA II)

Company: GENENTECH, INC./ROCHE
Clinical trial description: LAVOLTA I and LAVOLTA II are two parallel Phase 3 studies designed to evaluate the efficacy and safety of lebrikizumab in patients with uncontrolled asthma despite treatment with an inhaled corticosteroid and a second controller medication.
Type of patient needed: Adult patients with asthma who continue to have symptoms after receiving treatment with an inhaled corticosteroid and a second controller medication for at least 6 months may be considered for these clinical trials.
Additional information:
Lebrikizumab is a monoclonal antibody that binds to and inhibits IL-13 activity.
Posted: October 10, 2013

Learn how to participate  


 

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis (RIFF)

Company: GENENTECH, INC.
Clinical trial description: The phase II study (RIFF) is designed to evaluate the safety and efficacy of lebrikizumab in patients with idiopathic pulmonary fibrosis (IPF). The primary outcome measure for the study is Progression Free Survival.
Type of patient needed: Adult patients ≥ 40 years of age with a definite diagnosis of IPF according to the 2011 ATS/ERS/JRS/ALAT consensus statement on IPF within the previous 4 years from the time of screening.
Additional information:
Lebrikizumab is a monoclonal antibody that binds to and inhibits IL-13 activity.
Posted: October 10, 2013

Learn how to participate              

Expect the Xolair pregnancy registry

The Xolair Pregnancy Registry: An Observational Study of the Use and Safety of Xolair® (Omalizumab) During Pregnancy (EXPECT)

Company: GENENTECH, INC.
Clinical trial description: The Xolair Pregnancy Registry (EXPECT) is an observational study established by Genentech to obtain data on pregnancy outcomes in women who are exposed to Xolair® (omalizumab) during their pregnancy.
Type of patient needed: Women who have been exposed to at least one dose of Xolair within 8 weeks prior to conception or during pregnancy may be included in this registry.
Additional information:
Pregnancy Category B. There are no adequate and well-controlled studies of Xolair in pregnant women.
Posted: May 14, 2013

Learn how to participate

Disclaimer

The American College of Chest Physicians (CHEST), in furtherance of its mission of advancing research, has established this page to provide a list of clinical trials seeking individuals to serve as principal investigators or to otherwise participate. CHEST has neither conducted an independent investigation of the nature, quality, scientific merit, or subject matter of the clinical trials, nor has it established criteria or preconditions for those trials being listed on this page. CHEST, its officers, regents, members, and employees are not recommending or endorsing the listed trials or the companies sponsoring trials and specifically disclaims liability for damages of any kind arising out of a member, health-care provider, or any other individual’s participation in a listed trial.

Copyright 2018 © American College of Chest Physicians®

Printed from: http://www.chestnet.org/Guidelines-and-Resources/Resources/CHEST-Ebola-Resources